After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...

Northwestern Medicine scientists have developed a more effective method of delivering a cutting-edge cancer treatment, ...

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

"Lunit announces partnership with Roche to integrate AI into PD-L1 biomarker testing" was originally created and published by ...